As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Reviva Pharmaceuticals Holdi. The largest reported stake is Highbridge Capital Management, LLC's, at 9.9%. 21 filings are on record since July 1, 2025 (Schedule 13G, August 14, 2025).
Sell to companies like Reviva Pharmaceuticals Holdi? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Barclays PLC · Sole voting: 20 · Shared voting: 0 · Sole dispositive: 20 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 1,072,690 · Sole dispositive: 0 · Shared dispositive: 1,072,690 · SCHEDULE 13G/A, 2026-08-03
- · Reporting person: UBS Group AG · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-31
- · Holder: CVI Investments, Inc. · Percent: 4.9% · SCHEDULE 13G/A
- · Holder: Barclays PLC · Percent: 5.96% · SCHEDULE 13G
Reviva Pharmaceuticals Holdi has 21 Schedule 13D or 13G filings on record since 2025-07-01. 2 holders' latest filing reports 5% or more of common-stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Highbridge Capital Management, LLC | 9.9% | 8,000,000 | SCHEDULE 13G, 2025-08-14 | 2025-06-30 |
| Integrated Core Strategies (US) LLC | 8.2% | 1,072,690 | SCHEDULE 13G/A, 2026-08-03 | 2026-06-30 |
| CVI Investments, Inc. | 4.9% | 672,811 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Tang Capital Management, LLC | 4.8% | 3,399,975 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| 3.8% | 3,680,874 | SCHEDULE 13D/A, 2025-09-24 | 2025-09-22 | |
| 683 Capital Management, LLC | 3% | 3,492,500 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| 2.8% | 363,280 | SCHEDULE 13D/A, 2026-03-24 | 2026-03-20 | |
| UBS Group AG | 0% | 0 | SCHEDULE 13G/A, 2026-07-31 | 2026-06-30 |
| Barclays PLC | 0% | 20 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
Holding shares or following this stake? See who's behind Reviva Pharmaceuticals Holdi and the warning signs.
Free to see. No signup.
Keep reading
More on Reviva Pharmaceuticals Holdi and the records around it.
Companies that share a holder
- 683 CAPITAL MANAGEMENT, LLC also filed stake reports on 10 other companies: Perceptive Capital Solutions Corp (Aug 2026), Gossamer Bio, Inc. (Jun 2026), FRACTYL HEALTH, INC. (May 2026)
- UBS Group AG also filed stake reports on 13 other companies: Freight Technologies, Inc. (Nov 2026), Rising Dragon Acquisition Corp. (Nov 2026), Starlink AI Acquisition Corp (Nov 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
Watch Reviva Pharmaceuticals Holdi
Get an email when Reviva Pharmaceuticals Holdi files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Reviva Pharmaceuticals Holdi?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Reviva Pharmaceuticals Holdi: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Reviva Pharmaceuticals Holdi covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Integrated Core Strategies (US) LLC | 0 | 1,072,690 | 0 | 1,072,690 | SCHEDULE 13G/A, 2026-08-03 |
| Millennium Management LLC | 0 | 1,072,690 | 0 | 1,072,690 | SCHEDULE 13G/A, 2026-08-03 |
| Millennium Group Management LLC | 0 | 1,072,690 | 0 | 1,072,690 | SCHEDULE 13G/A, 2026-08-03 |
| Israel A. Englander | 0 | 1,072,690 | 0 | 1,072,690 | SCHEDULE 13G/A, 2026-08-03 |
| UBS Group AG | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-07-31 |
| Barclays PLC | 20 | 0 | 20 | 0 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Reviva Pharmaceuticals Holdi by CUSIP 76152G209 and gives its principal executive office as 10080 N Wolfe Road, Suite SW3-200, Cupertino, CA 95014 (SCHEDULE 13G/A, 2026-08-13).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-01 | Bhat Laxminarayan | 5.2% | SCHEDULE 13D/A |
| 2025-07-01 | Parag Saxena | 8.7% | SCHEDULE 13D/A |
| 2025-07-01 | CVI Investments, Inc. | 5.9% | SCHEDULE 13G |
| 2025-08-14 | Highbridge Capital Management, LLC | 9.9% | SCHEDULE 13G |
| 2025-08-14 | Tang Capital Management, LLC | 4.8% | SCHEDULE 13G/A |
| 2025-08-14 | CVI Investments, Inc. | 4.9% | SCHEDULE 13G/A |
| 2025-09-24 | Bhat Laxminarayan | 3.8% | SCHEDULE 13D/A |
| 2025-09-24 | Parag Saxena | 6.2% | SCHEDULE 13D/A |
| 2025-09-29 | 683 Capital Management, LLC | 5.36% | SCHEDULE 13G |
| 2025-12-22 | Parag Saxena | 5.2% | SCHEDULE 13D/A |
| 2026-01-16 | Integrated Core Strategies (US) LLC | 2.8% | SCHEDULE 13G/A |
| 2026-02-17 | 683 Capital Management, LLC | 3% | SCHEDULE 13G/A |
| 2026-03-24 | Parag Saxena | 2.8% | SCHEDULE 13D/A |
| 2026-03-25 | CVI Investments, Inc. | 5.2% | SCHEDULE 13G |
| 2026-03-30 | Integrated Core Strategies (US) LLC | 6.2% | SCHEDULE 13G |
| 2026-05-07 | UBS Group AG | 5.8% | SCHEDULE 13G |
| 2026-05-14 | Barclays PLC | 5.96% | SCHEDULE 13G |
| 2026-05-15 | CVI Investments, Inc. | 4.9% | SCHEDULE 13G/A |
| 2026-07-31 | UBS Group AG | 0% | SCHEDULE 13G/A |
| 2026-08-03 | Integrated Core Strategies (US) LLC | 8.2% | SCHEDULE 13G/A |
| 2026-08-13 | Barclays PLC | 0% | SCHEDULE 13G/A |
Questions about who owns Reviva Pharmaceuticals Holdi
Who owns Reviva Pharmaceuticals Holdi?
On this page, 2 holders' latest ownership filings report 5% or more of Reviva Pharmaceuticals Holdi: Highbridge Capital Management, LLC (9.9%, Schedule 13G, filed 2025-08-14) and Integrated Core Strategies (US) LLC (8.2%, Schedule 13G/A, filed 2026-08-03).
Who are the largest shareholders of Reviva Pharmaceuticals Holdi?
By the share each holder's latest filing reports, the largest holders of Reviva Pharmaceuticals Holdi on this page are Highbridge Capital Management, LLC (9.9%) and Integrated Core Strategies (US) LLC (8.2%).
When did Highbridge Capital Management, LLC buy into Reviva Pharmaceuticals Holdi?
The filings give report dates, not purchase dates. The earliest filing from Highbridge Capital Management, LLC on this page is the Schedule 13G, filed 2025-08-14, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 21 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Reviva Pharmaceuticals Holdi. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.